Benchmark Initiates Coverage on Kamada (NASDAQ:KMDA)

Benchmark started coverage on shares of Kamada (NASDAQ:KMDA) in a research note published on Friday, Marketbeat reports. The brokerage issued a buy rating and a $15.00 price objective on the biotechnology company’s stock.

KMDA has been the subject of several other research reports. HC Wainwright restated a “buy” rating and set a $11.00 target price on shares of Kamada in a research note on Thursday, March 6th. StockNews.com upgraded shares of Kamada from a “buy” rating to a “strong-buy” rating in a research note on Thursday, March 13th.

Kamada Price Performance

Shares of KMDA opened at $6.72 on Friday. Kamada has a one year low of $4.74 and a one year high of $9.16. The company’s fifty day moving average price is $7.19 and its 200 day moving average price is $6.25. The company has a market capitalization of $386.27 million, a PE ratio of 24.00, a price-to-earnings-growth ratio of 0.97 and a beta of 0.97.

Kamada Announces Dividend

The company also recently disclosed a — dividend, which will be paid on Monday, April 7th. Stockholders of record on Monday, March 17th will be issued a dividend of $0.20 per share. The ex-dividend date of this dividend is Monday, March 17th.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. JPMorgan Chase & Co. bought a new stake in Kamada in the 4th quarter valued at $67,000. Public Employees Retirement System of Ohio acquired a new stake in shares of Kamada during the 3rd quarter valued at about $77,000. NewEdge Advisors LLC increased its stake in Kamada by 54.2% in the fourth quarter. NewEdge Advisors LLC now owns 23,496 shares of the biotechnology company’s stock valued at $143,000 after acquiring an additional 8,260 shares during the period. Geode Capital Management LLC raised its position in Kamada by 5.6% in the fourth quarter. Geode Capital Management LLC now owns 29,289 shares of the biotechnology company’s stock worth $178,000 after purchasing an additional 1,549 shares in the last quarter. Finally, Aristides Capital LLC lifted its stake in Kamada by 12.1% during the fourth quarter. Aristides Capital LLC now owns 63,485 shares of the biotechnology company’s stock worth $387,000 after purchasing an additional 6,850 shares during the period. 20.38% of the stock is currently owned by institutional investors and hedge funds.

Kamada Company Profile

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.